BRAF and melanoma: In vitro, BRAF inhibitor (BRAFi)-resistant melanoma cells characterized by dedifferentiated mesenchymal-like or NCSC-like phenotypes display a pronounced mechanosensitivity and elevated mechanosignaling when plated on rigid collagen substrates [62].